Ilyang Pharmaceutical Co Ltd represents values of excellence, innovation, and commitment to health and well-being. With a strong corporate philosophy deeply rooted in quality, integrity, and social responsibility, Ilyang Pharmaceutical is dedicated to providing high-quality pharmaceutical products and medical services to improve people's lives. The company prioritizes research and development, aiming to develop innovative solutions and contribute to advancements in the healthcare industry. Ilyang Pharmaceutical Co Ltd's commitment to delivering effective and safe pharmaceuticals with a customer-centric approach has earned them a reputation as a trusted and reliable healthcare partner.

Ilyang Pharmaceutical Co Ltd is primarily present in South Korea.

Ilyang Pharmaceutical Co Ltd has achieved several significant milestones throughout its history. The company has successfully expanded its product portfolio, focusing on innovative and high-quality pharmaceutical products. Ilyang Pharmaceutical Co Ltd has also gained recognition for its dedication to research and development, leading to the discovery and development of new medicines. Additionally, the company has successfully established a strong international presence, expanding its market reach and partnerships worldwide. Furthermore, Ilyang Pharmaceutical Co Ltd has been consistently recognized for its commitment to delivering superior healthcare solutions, contributing to the well-being of individuals and communities.

Ilyang Pharmaceutical Co Ltd is a renowned pharmaceutical company with a rich history and background. Founded in [insert year], the company has established itself as a leader in the healthcare industry. Over the years, Ilyang Pharmaceutical Co Ltd has consistently delivered innovative and high-quality healthcare products to improve the well-being of individuals worldwide. With a strong commitment to research and development, the company has successfully launched numerous breakthrough drugs in various therapeutic areas. Ilyang Pharmaceutical Co Ltd's dedication to excellence, combined with its extensive expertise and global reach, has positioned it as a trusted name in the pharmaceutical sector.

The main competitors of Ilyang Pharmaceutical Co Ltd in the market include Johnson & Johnson, Pfizer Inc., Novartis AG, and Merck & Co. These companies are major players in the pharmaceutical industry, known for their extensive product portfolios and global presence. Despite facing competition from these established firms, Ilyang Pharmaceutical Co Ltd strives to differentiate itself by leveraging its unique offerings and strengthening its market position. By focusing on innovation, quality, and strategic partnerships, Ilyang Pharmaceutical Co Ltd aims to maintain its competitive edge and capture a significant market share in the industry.

Ilyang Pharmaceutical Co Ltd is primarily active in the pharmaceutical industry.

The business model of Ilyang Pharmaceutical Co Ltd is focused on developing, manufacturing, and distributing pharmaceutical products. As a leading pharmaceutical company, Ilyang Pharma aims to provide innovative and high-quality healthcare solutions to improve the well-being of individuals. With a diverse range of products spanning various therapeutic areas such as cardiovascular, respiratory, gastrointestinal, and central nervous system disorders, Ilyang Pharma strives to enhance the quality of life for patients globally. By investing in research and development, ensuring regulatory compliance, and fostering strategic partnerships, Ilyang Pharmaceutical Co Ltd demonstrates its commitment to delivering effective and reliable pharmaceutical solutions.

KGV ไม่สามารถคำนวณได้สำหรับ Ilyang Pharmaceutical Co ในขณะนี้

ขณะนี้ไม่สามารถคำนวณ KUV สำหรับ Ilyang Pharmaceutical Co ได้

AlleAktien คุณภาพสกอร์สำหรับ Ilyang Pharmaceutical Co คือ 4/10.

ขณะนี้ไม่สามารถคำนวณยอดขายสำหรับ Ilyang Pharmaceutical Co ได้

ขณะนี้ไม่สามารถคำนวณกำไรสำหรับ Ilyang Pharmaceutical Co ได้

Ilyang Pharmaceutical Co Ltd is a leading pharmaceutical company in Korea, manufacturing innovative and high-quality medications since its establishment in 1941. The company is divided into three main areas: pharmaceuticals, medical devices, and cosmeceuticals. Ilyang develops and produces a wide range of prescription medications, including antidiabetics, cardiovascular drugs, antipsychotics, antibiotics, and cancer medications. In the medical device sector, Ilyang offers products for diagnosis, monitoring, and treatment of diseases, such as ultrasound devices, blood pressure monitors, and EKG devices. In the cosmeceuticals industry, Ilyang produces high-quality skincare and makeup products using natural ingredients to promote skin health and enhance consumers' self-esteem. The company aims to meet the highest quality standards in the production of medications, medical devices, and cosmetics, working closely with regulatory agencies to ensure compliance with national and international health and safety standards. Ilyang is also focused on expanding its presence in the global market through partnerships and research and development investments. Overall, Ilyang Pharmaceutical Co Ltd has a diverse business model based on high-quality products and continuous innovation, positioning itself as a significant player in the global market for medications, medical devices, and cosmetics, with the potential to continue playing a crucial role in the future.

Ilyang Pharmaceutical Co จ่ายเงินปันผล 150 KRW ผ่าน ครั้งในหนภายในหนึ่งปี.

ปัจจุบันไม่สามารถคำนวณเงินปันผลสำหรับ Ilyang Pharmaceutical Co หรือบริษัทไม่จ่ายเงินปันผล.

ISIN ของ Ilyang Pharmaceutical Co คือ KR7007570005

ตัวย่อของ Ilyang Pharmaceutical Co คือ 007570.KS

ภายในช่วง 12 เดือนที่ผ่านมา Ilyang Pharmaceutical Co จ่ายเงินปันผลทั้งหมด 150 KRW นี้เทียบเท่ากับอัตราผลตอบแทนจากเงินปันผลประมาณ 1.31 % สำหรับ 12 เดือนข้างหน้า Ilyang Pharmaceutical Co คาดว่าจะจ่ายเงินปันผลทั้งหมด 150 KRW

อัตราผลตอบแทนเงินปันผลของ Ilyang Pharmaceutical Co ในปัจจุบันคือ 1.31 %

Ilyang Pharmaceutical Co จ่ายเงินปันผลทุกไตรมาส การจ่ายเงินปันผลจะเกิดขึ้นในเดือน มกราคม, มกราคม, มกราคม, มกราคม

Ilyang Pharmaceutical Co จ่ายเงินปันผลทุกปีในช่วง 5 ปีที่ผ่านมา.

คาดว่าในช่วง 12 เดือนข้างหน้าจะมีการจ่ายเงินปันผลทั้งหมด 150 KRW ซึ่งเทียบเท่ากับผลตอบแทนจากเงินปันผลร้อยละ 1.31 %

Ilyang Pharmaceutical Co ถูกจัดให้อยู่ในภาคส่วน 'สุขภาพ'

เพื่อรับเงินปันผลล่าสุดของ Ilyang Pharmaceutical Co ในวันที่ 1/5/2567 ที่มูลค่า 150 KRW คุณจะต้องถือหุ้นไว้ในพอร์ตก่อนวันที่เป็น Ex-Tag ในวันที่ 27/12/2566

การจ่ายเงินปันผลครั้งล่าสุดเกิดขึ้นเมื่อวันที่ 1/5/2567

ในปี 2024 บริษัท Ilyang Pharmaceutical Co ได้จ่ายเงินปันผลเป็นจำนวน 150 KRW

เงินปันผลของ Ilyang Pharmaceutical Co จะถูกจ่ายใน KRW